BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:13 PM
Aug 08, 2019
 |  BC Extra  |  Preclinical News

Aug. 8 Preclinical Quick Takes: Mayo Clinic assay for residual disease; plus camouflage for bacterial agents, Elicio's KRAS vaccine and more

Mayo Clinic liquid biopsy identifies breast cancer residual disease
A Mayo Clinic team reported in a Science Translational Medicine article that a personalized multiplex sequencing approach called TARDIS (targeted digital sequencing) could accurately distinguish pathological complete response and residual disease following cancer treatment by simultaneously detecting multiple patient-specific cancer mutations in circulating tumor DNA (ctDNA). In nine triple-negative and 11 estrogen receptor-positive breast cancer patients treated with neoadjuvant therapies, the approach correctly identified patients with residual disease with areas under the curve (AUCs) of 1 and 0.89, respectively.

Membrane camouflage for bacterial agents
A Shanghai Jiao Tong University team showed that coating bacteria with erythrocyte membranes could prevent their rapid clearance and inflammatory...

Read the full 536 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >